Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022006105 - COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS

Publication Number WO/2022/006105
Publication Date 06.01.2022
International Application No. PCT/US2021/039613
International Filing Date 29.06.2021
IPC
C12N 15/11 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Applicants
  • AVROBIO, INC. [US]/[US]
Inventors
  • MASON, Chris
  • COOPER, Oliver
  • PLASSCHAERT, Robert
Agents
  • BELLIVEAU, Michael J.
Priority Data
63/047,74402.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS
(FR) COMPOSITIONS ET MÉTHODES POUR TRAITER DES TROUBLES NEUROCOGNITIFS
Abstract
(EN) Described herein are compositions and methods for treating a subject having or at risk of developing a neurocognitive disorder, such as Alzheimer's disease or Nasu-Hakola disease. For example, using the compositions and methods of the disclosure, a subject having or at risk of developing a neurocognitive disorder may be administered one or more cells that contain a transgene encoding triggering receptor expressed on myeloid cells two (TREM2), such as a population of CD34+ hematopoietic stem or progenitor cells that express TREM2, thereby treating or preventing the disorder.
(FR) L'invention concerne des compositions et des méthodes pour traiter un sujet présentant ou risquant de développer un trouble neurocognitif, tel que la maladie d'Alzheimer ou la maladie de Nasu-Hakola. Par exemple, à l'aide des compositions et des méthodes de l'invention, un sujet ayant ou présentant un risque de développer un trouble neurocognitif peut se voir administrer une ou plusieurs cellules qui contiennent un transgène codant un récepteur activateur exprimé sur les cellules myéloïdes 2 (TREM2), telles qu'une population de cellules souches hématopoïétiques CD34+ ou de cellules progénitrices hématopoïétiques CD34+ qui expriment le TREM2, ce qui permet de traiter ou de prévenir le trouble.
Latest bibliographic data on file with the International Bureau